Holen Sie sich die Stockscreener-App
42.00
1.28%
0.53
Handel nachbörslich:
42.00
Schlusskurs vom Vortag:
$41.47
Offen:
$41.41
24-Stunden-Volumen:
486.74K
Relative Volume:
1.18
Marktkapitalisierung:
$3.18B
Einnahmen:
$384.10M
Nettoeinkommen (Verlust:
$-9.07M
KGV:
-300.00
EPS:
-0.14
Netto-Cashflow:
$11.10M
1W Leistung:
+2.41%
1M Leistung:
+1.74%
6M Leistung:
+50.38%
1J Leistung:
+109.37%
1-Tages-Spanne:
$40.77
$42.47
1-Wochen-Bereich:
$40.33
$42.47
52-Wochen-Spanne:
$17.82
$42.98
Kiniksa Pharmaceuticals International Plc Stock (KNSA) Company Profile
Firmenname
Kiniksa Pharmaceuticals International Plc
Sektor
Telefon
(781) 431-9100
Adresse
23 OLD BOND STREET, FLOOR 3, LONDON
Vergleichen Sie KNSA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
KNSA
Kiniksa Pharmaceuticals International Plc
|
42.00 | 3.14B | 384.10M | -9.07M | 11.10M | -0.14 |
|
ZTS
Zoetis Inc
|
122.76 | 53.87B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.83 | 45.71B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
9.84 | 43.73B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
30.32 | 34.49B | 16.88B | 666.71M | 251.19M | 0.6132 |
|
UTHR
United Therapeutics Corp
|
507.00 | 22.00B | 3.08B | 1.24B | 1.07B | 25.61 |
Kiniksa Pharmaceuticals International Plc Stock (KNSA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-09-29 | Eingeleitet | TD Cowen | Buy |
| 2025-03-13 | Eingeleitet | Citigroup | Buy |
| 2024-09-13 | Eingeleitet | Jefferies | Buy |
| 2024-05-03 | Eingeleitet | Wells Fargo | Overweight |
| 2020-06-29 | Bestätigt | BofA Securities | Buy |
| 2020-04-01 | Eingeleitet | BofA/Merrill | Buy |
| 2019-03-11 | Eingeleitet | Barclays | Overweight |
| 2018-12-12 | Bestätigt | Wedbush | Outperform |
| 2018-06-19 | Eingeleitet | JMP Securities | Mkt Outperform |
Alle ansehen
Kiniksa Pharmaceuticals International Plc Aktie (KNSA) Neueste Nachrichten
Kiniksa Pharmaceuticals International (NASDAQ:KNSA) COO Sells $500,714.88 in Stock - MarketBeat
Kiniksa Pharmaceuticals International Insider Sold Shares Worth $500,715, According to a Recent SEC Filing - marketscreener.com
Kiniksa Pharmaceuticals Executives Sell Shares - TradingView — Track All Markets
US High Growth Tech Stocks to Watch - simplywall.st
Braidwell LP Sells 860,329 Shares of Kiniksa Pharmaceuticals International, plc $KNSA - MarketBeat
Why Kiniksa Pharmaceuticals International, plc (KNSA) is Poised to Beat Earnings Estimates Again - MSN
Nebula Research & Development LLC Has $1.93 Million Stake in Kiniksa Pharmaceuticals International, plc $KNSA - MarketBeat
Insider Selling: Kiniksa Pharmaceuticals International (NASDAQ:KNSA) CFO Sells 42,841 Shares of Stock - MarketBeat
Kiniksa Pharma CFO Ragosa sells shares worth $1.77m By Investing.com - Investing.com Nigeria
Kiniksa Pharmaceuticals CFO Sells Shares - TradingView — Track All Markets
Jump Financial LLC Takes Position in Kiniksa Pharmaceuticals International, plc $KNSA - MarketBeat
Kiniksa Pharmaceuticals International, plc $KNSA Shares Bought by Walleye Capital LLC - MarketBeat
Arrowstreet Capital Limited Partnership Makes New Investment in Kiniksa Pharmaceuticals International, plc $KNSA - MarketBeat
Fisher Asset Management LLC Has $2.83 Million Stock Position in Kiniksa Pharmaceuticals International, plc $KNSA - Defense World
Wedbush Reiterates Outperform Rating for Kiniksa Pharmaceuticals International (NASDAQ:KNSA) - MarketBeat
Traders Buy High Volume of Call Options on Kiniksa Pharmaceuticals International (NASDAQ:KNSA) - MarketBeat
Franklin Resources Inc. Acquires 41,632 Shares of Kiniksa Pharmaceuticals International, plc $KNSA - MarketBeat
Kiniksa Pharmaceuticals International’s (KNSA) “Outperform” Rating Reaffirmed at Wedbush - Defense World
Universal Beteiligungs und Servicegesellschaft mbH Makes New Investment in Kiniksa Pharmaceuticals International, plc $KNSA - MarketBeat
Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Kiniksa (KNSA) Q3 2025 Earnings Call Transcript - The Globe and Mail
Wall Street Analysts Think Kiniksa Pharmaceuticals International, plc (KNSA) Could Surge 29.3%: Read This Before Placing a Bet - MSN
Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Reaches New 12-Month HighTime to Buy? - MarketBeat
AXQ Capital LP Makes New $289,000 Investment in Kiniksa Pharmaceuticals International, plc $KNSA - MarketBeat
200,574 Shares in Kiniksa Pharmaceuticals International, plc $KNSA Purchased by Hillsdale Investment Management Inc. - MarketBeat
Catalyst Funds Management Pty Ltd Takes $493,000 Position in Kiniksa Pharmaceuticals International, plc $KNSA - MarketBeat
Insider Selling: Kiniksa Pharmaceuticals International (NASDAQ:KNSA) COO Sells 12,470 Shares of Stock - MarketBeat
SG Americas Securities LLC Acquires 127,126 Shares of Kiniksa Pharmaceuticals International, plc $KNSA - MarketBeat
Kiniksa Pharma COO Tessari sells shares worth $514,224 By Investing.com - Investing.com South Africa
Kiniksa Pharma COO Tessari sells shares worth $514,224 - Investing.com
[Form 4] Kiniksa Pharmaceuticals International, plc Insider Trading Activity - Stock Titan
Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Sets New 52-Week HighTime to Buy? - MarketBeat
Los Angeles Capital Management LLC Sells 36,570 Shares of Kiniksa Pharmaceuticals International, plc $KNSA - MarketBeat
From Olema To Insmed: Are These High-Flying Biotechs Still Worth Buying? - RTTNews
Kiniksa Pharmaceuticals International, plc (KNSA) Presents at Jefferies London Healthcare Conference 2025Slideshow (NASDAQ:KNSA) 2025-11-18 - Seeking Alpha
Savant Capital LLC Invests $398,000 in Kiniksa Pharmaceuticals International, plc $KNSA - MarketBeat
Mark Ragosa Sells 19,900 Shares of Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Stock - MarketBeat
Kiniksa Rides ARCALYST Growth To Outpace The S&P 500 - Finimize
Exploring High Growth Tech Stocks in the US Market - Yahoo Finance
Kiniksa Pharmaceuticals to Present at Jefferies Global Healthcare Conference in London - The Manila Times
Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Increases 5.3% This Week, Taking Five-year Gains to 166% - 富途牛牛
Finanzdaten der Kiniksa Pharmaceuticals International Plc-Aktie (KNSA)
Umsatz
Nettogewinn
Free Cashflow
ENV
12.55%
0.77%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):